BRIEF published on 02/04/2025 at 10:40, 1 year 2 months ago Valerio Therapeutics opts for strategic refocusing Clinical Trials Oncology Financial Strategy Medical Innovation Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 2 months ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce un recentrage stratégique pour se concentrer sur le développement de médicaments early-stage et assurer une croissance durable. La société cherche un accord de financement à long terme Développement Financement Restructuration Médicaments Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 2 months ago Inside Information / Other news releases Valerio Therapeutics refocuses strategy, discontinuing clinical trials for financial reasons. Focus on early-stage drug development Clinical Trials Financial Challenges Valerio Therapeutics Strategy Refocus Early-stage Development
BRIEF published on 10/01/2024 at 00:56, 1 year 6 months ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 Résultats Financiers R&D Essai Clinique Valerio Therapeutics Anticorps À Domaine Unique
BRIEF published on 10/01/2024 at 00:56, 1 year 6 months ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
PRESS RELEASE published on 10/01/2024 at 00:51, 1 year 6 months ago Inside Information: News release on accounts, results Valerio Therapeutics annonce ses résultats financiers du Premier Semestre 2024 et fait le point sur ses activités, y compris l'acquisition d'Emglev Therapeutics et le développement de la plateforme PlatONTM Résultats Financiers Biotechnologie Valerio Therapeutics Emglev Therapeutics Plateforme PlatONTM
BRIEF published on 10/01/2024 at 00:45, 1 year 6 months ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
BRIEF published on 10/01/2024 at 00:45, 1 year 6 months ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 et ses mises à jour stratégiques Résultats Financiers Plateforme PlatONTM Acquisition D'Emglev Essai Clinique VIO-01 Innovations Thérapeutiques
PRESS RELEASE published on 10/01/2024 at 00:40, 1 year 6 months ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 22:40, 1 year 6 months ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Published on 04/07/2026 at 15:00, 5 hours 28 minutes ago Karbon-X Expands Enterprise Climate Platform Through Strategic Partnership with carbon-connect AG
Published on 04/07/2026 at 14:45, 5 hours 43 minutes ago Predictiv AI Introduces Clinical AI Reasoning Platform, Files Patent for Domain-Specific Clinical AI Methodology
Published on 04/07/2026 at 14:40, 5 hours 48 minutes ago bioEnergy Development Inc. Advances Domestic Activated Carbon Production Worth Up to $30 Million Over 5 Years
Published on 04/07/2026 at 14:30, 5 hours 58 minutes ago Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Published on 04/07/2026 at 14:30, 5 hours 58 minutes ago Sekur Private Data Announces Philip Oakley and Kenneth Rogers as Members of Strategic Advisory Board
Published on 04/07/2026 at 17:45, 2 hours 42 minutes ago VAZIVA SA: Mise à jour des modalités de l’émission d’obligations convertibles en actions nouvelles (OCA) de 8 M€ à un taux de 7,0% par an et à maturité de 3 ans
Published on 04/07/2026 at 17:45, 2 hours 42 minutes ago FIGEAC AÉRO: INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/07/2026 at 17:40, 2 hours 47 minutes ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 04/07/2026 at 16:32, 3 hours 55 minutes ago Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline.
Published on 04/07/2026 at 18:00, 2 hours 28 minutes ago LDC : Chiffre d’affaires du 4 ème trimestre 2025-2026. Solide croissance du chiffre d’affaires au 4ème trimestre 2025-2026 et révision à la hausse des objectifs.
Published on 04/07/2026 at 17:57, 2 hours 30 minutes ago Peugeot Invest publishes its 2025 Universal Registration Document
Published on 04/07/2026 at 17:57, 2 hours 30 minutes ago Mise à disposition du Document d’enregistrement universel 2025
Published on 04/07/2026 at 17:45, 2 hours 42 minutes ago ENGIE accelerates the deployment of battery storage with nearly 400 MW of new projects in Europe
Published on 04/07/2026 at 17:45, 2 hours 42 minutes ago ENGIE accélère le déploiement du stockage par batteries avec près de 400 MW de nouveaux projets en Europe
